NO20062663L - Nukleinsyre som spesifikt binder bioaktivt ghrelin - Google Patents
Nukleinsyre som spesifikt binder bioaktivt ghrelinInfo
- Publication number
- NO20062663L NO20062663L NO20062663A NO20062663A NO20062663L NO 20062663 L NO20062663 L NO 20062663L NO 20062663 A NO20062663 A NO 20062663A NO 20062663 A NO20062663 A NO 20062663A NO 20062663 L NO20062663 L NO 20062663L
- Authority
- NO
- Norway
- Prior art keywords
- nucleic acid
- specifically binds
- bioactive ghrelin
- binds bioactive
- ghrelin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03025743 | 2003-11-10 | ||
PCT/EP2004/012739 WO2005049828A1 (en) | 2003-11-10 | 2004-11-10 | Nucleic acids specifically binding bioactive ghrelin |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062663L true NO20062663L (no) | 2006-08-09 |
Family
ID=34610046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062663A NO20062663L (no) | 2003-11-10 | 2006-06-09 | Nukleinsyre som spesifikt binder bioaktivt ghrelin |
Country Status (19)
Country | Link |
---|---|
US (2) | US20070031840A1 (es) |
EP (1) | EP1682662A1 (es) |
JP (1) | JP4823067B2 (es) |
KR (1) | KR20060125743A (es) |
CN (1) | CN1894407A (es) |
AP (1) | AP2006003618A0 (es) |
AU (1) | AU2004291656A1 (es) |
BR (1) | BRPI0415872A (es) |
CA (1) | CA2544805A1 (es) |
CR (1) | CR8388A (es) |
EA (1) | EA009376B1 (es) |
EC (1) | ECSP066559A (es) |
IL (1) | IL175443A0 (es) |
MA (1) | MA28153A1 (es) |
NO (1) | NO20062663L (es) |
OA (1) | OA13282A (es) |
TN (1) | TNSN06132A1 (es) |
WO (1) | WO2005049828A1 (es) |
ZA (1) | ZA200603435B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1530635B1 (en) * | 2002-08-01 | 2011-06-15 | Noxxon Pharma AG | Ghrelin binding nucleic acids |
JP5435864B2 (ja) | 2004-05-28 | 2014-03-05 | アシュラジェン インコーポレイテッド | マイクロrnaに関与する方法および組成物 |
DK2302055T3 (da) | 2004-11-12 | 2014-10-13 | Asuragen Inc | Fremgangsmåder og sammensætninger involverende miRNA og miRNA-inhibitormolekyler |
UY29460A1 (es) * | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
EP2115138A2 (en) * | 2006-09-19 | 2009-11-11 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
CA2663962A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-15, mir-26, mir-31,mir-145, mir-147, mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention |
AU2007333107A1 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-21 regulated genes and pathways as targets for therapeutic intervention |
EP2104737B1 (en) * | 2006-12-08 | 2013-04-10 | Asuragen, INC. | Functions and targets of let-7 micro rnas |
CN101627121A (zh) * | 2006-12-08 | 2010-01-13 | 奥斯瑞根公司 | 作为治疗干预的靶标的miRNA调控基因和路径 |
CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
US20090227533A1 (en) * | 2007-06-08 | 2009-09-10 | Bader Andreas G | miR-34 Regulated Genes and Pathways as Targets for Therapeutic Intervention |
EP2198050A1 (en) | 2007-09-14 | 2010-06-23 | Asuragen, INC. | Micrornas differentially expressed in cervical cancer and uses thereof |
WO2009052386A1 (en) * | 2007-10-18 | 2009-04-23 | Asuragen, Inc. | Micrornas differentially expressed in lung diseases and uses thereof |
US8071562B2 (en) * | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
WO2009086156A2 (en) * | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
EP2260110B1 (en) * | 2008-02-08 | 2014-11-12 | Asuragen, INC. | miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS |
WO2009111643A2 (en) * | 2008-03-06 | 2009-09-11 | Asuragen, Inc. | Microrna markers for recurrence of colorectal cancer |
WO2009154835A2 (en) * | 2008-03-26 | 2009-12-23 | Asuragen, Inc. | Compositions and methods related to mir-16 and therapy of prostate cancer |
EP2285960B1 (en) | 2008-05-08 | 2015-07-08 | Asuragen, INC. | Compositions and methods related to mir-184 modulation of neovascularization or angiogenesis |
US20100179213A1 (en) * | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
US20110105389A1 (en) | 2009-10-30 | 2011-05-05 | Hoveyda Hamid R | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same |
EP2663640B1 (en) * | 2011-01-10 | 2020-11-04 | APTARION biotech AG | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614395A (en) * | 1988-03-08 | 1997-03-25 | Ciba-Geigy Corporation | Chemically regulatable and anti-pathogenic DNA sequences and uses thereof |
US5475096A (en) * | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
WO1996034879A1 (en) * | 1995-05-03 | 1996-11-07 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
US5780221A (en) * | 1995-05-03 | 1998-07-14 | Whitehead Institute For Biomedical Research | Identification of enantiomeric ligands |
WO2001087335A2 (en) * | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
US20030211967A1 (en) * | 2001-05-07 | 2003-11-13 | Bryant Henry Uhlman | Method for selectively inhibiting ghrelin action |
US6967237B2 (en) * | 2000-05-30 | 2005-11-22 | Merck & Co., Inc. | Ghrelin analogs |
EP1530635B1 (en) * | 2002-08-01 | 2011-06-15 | Noxxon Pharma AG | Ghrelin binding nucleic acids |
UY29460A1 (es) * | 2005-04-08 | 2006-11-30 | Noxxon Pharma Ag | Acidos nucleicos de union a ghrelin |
-
2004
- 2004-11-10 EA EA200600735A patent/EA009376B1/ru not_active IP Right Cessation
- 2004-11-10 WO PCT/EP2004/012739 patent/WO2005049828A1/en active Application Filing
- 2004-11-10 CN CNA2004800377977A patent/CN1894407A/zh active Pending
- 2004-11-10 AU AU2004291656A patent/AU2004291656A1/en not_active Abandoned
- 2004-11-10 CA CA002544805A patent/CA2544805A1/en not_active Abandoned
- 2004-11-10 KR KR1020067009024A patent/KR20060125743A/ko not_active Application Discontinuation
- 2004-11-10 BR BRPI0415872-5A patent/BRPI0415872A/pt not_active IP Right Cessation
- 2004-11-10 AP AP2006003618A patent/AP2006003618A0/xx unknown
- 2004-11-10 EP EP04797787A patent/EP1682662A1/en not_active Ceased
- 2004-11-10 US US10/578,938 patent/US20070031840A1/en not_active Abandoned
- 2004-11-10 OA OA1200600147A patent/OA13282A/en unknown
- 2004-11-10 JP JP2006538786A patent/JP4823067B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-02 ZA ZA200603435A patent/ZA200603435B/en unknown
- 2006-05-04 IL IL175443A patent/IL175443A0/en unknown
- 2006-05-09 TN TNP2006000132A patent/TNSN06132A1/fr unknown
- 2006-05-10 MA MA29015A patent/MA28153A1/fr unknown
- 2006-05-10 EC EC2006006559A patent/ECSP066559A/es unknown
- 2006-05-10 CR CR8388A patent/CR8388A/es not_active Application Discontinuation
- 2006-06-09 NO NO20062663A patent/NO20062663L/no not_active Application Discontinuation
-
2010
- 2010-02-24 US US12/711,415 patent/US20100261291A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA009376B1 (ru) | 2007-12-28 |
ECSP066559A (es) | 2006-11-24 |
US20070031840A1 (en) | 2007-02-08 |
ZA200603435B (en) | 2007-06-27 |
OA13282A (en) | 2007-01-31 |
CA2544805A1 (en) | 2005-06-02 |
BRPI0415872A (pt) | 2007-01-09 |
AP2006003618A0 (en) | 2006-06-30 |
US20100261291A1 (en) | 2010-10-14 |
EA200600735A1 (ru) | 2006-10-27 |
CN1894407A (zh) | 2007-01-10 |
MA28153A1 (fr) | 2006-09-01 |
KR20060125743A (ko) | 2006-12-06 |
JP2007513608A (ja) | 2007-05-31 |
EP1682662A1 (en) | 2006-07-26 |
JP4823067B2 (ja) | 2011-11-24 |
AU2004291656A1 (en) | 2005-06-02 |
TNSN06132A1 (fr) | 2007-11-15 |
WO2005049828A1 (en) | 2005-06-02 |
IL175443A0 (en) | 2006-09-05 |
CR8388A (es) | 2006-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062663L (no) | Nukleinsyre som spesifikt binder bioaktivt ghrelin | |
NO20052058D0 (no) | Behandling av influensa. | |
WO2005046603A3 (en) | Pyridine compounds | |
NO20055381D0 (no) | Enkel inkubasjon, multisting-endoskopisk sutursystem | |
IS2722B (is) | 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum | |
NO20053041D0 (no) | Behandling av diabetes. | |
WO2004064595A3 (en) | Multivalent constructs for therapeutic and diagnostic applications | |
NO20041452L (no) | 17-beta-hydroksysteroid-dehydrogenase type 3-inhibitorer for behandling av androgenavhengige sykdommer. | |
NO20035496D0 (no) | Substituerte sulfonamidforbindelser, fremgangsmåte for deres anvendelse sommedikament til behandling av CNS-forstyrrelser, overvekt og typeII-diabetes | |
WO2004113275A3 (en) | Methods and compositions for treating amyloid-related diseases | |
WO2007073497A3 (en) | Calcium channel antagonists | |
WO2007075852A3 (en) | Calcium channel antagonists | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
ATE325124T1 (de) | Ccr1-rezeptor-antagonisten zur behandlung u.a. demyelinisierender entzündlicher erkrankungen | |
ATE399557T1 (de) | Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen | |
BR0300119B1 (pt) | composiÇço aquosa. | |
EA200602154A1 (ru) | Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5 | |
ITMO20020337A1 (it) | Dispositivo per anastomosi. | |
NO20054346L (no) | Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander | |
DK1713438T3 (da) | Medicinsk sæbe | |
NO20061425L (no) | Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin | |
CY2011018I1 (el) | Νεα κρυσταλλικη μορφη toy 8-kyan-1-kykλoπpoπyλ-7-(1s,6s-2,8-διαζαδικυκλο[4.3.0]εννεαν-8-υλ)-6-φθορο-1,4-διυδρο-4-οξο-3-κινολινο-καρβοξυλικου οξεος | |
WO2002086504A3 (en) | Individualization of therapy with gastroesophageal reflux disease agents | |
NO20054034D0 (no) | Fremgangsmate for behandling av hypotyroidisme. | |
IS7609A (is) | 2,5-tvíútskipt 3-merkaptópentansýra |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |